|
Randomized double blind controlled, phase I clinical trial, to assess safety, reactogenicity and immunogenicity of the 638 vaccine candidate, in healthy female and male children and adolescents aged from 5 to 17 years old from Cienfuegos Province, Cuba. |
11/10/2013 |
FINLAY |
|
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months. |
2011-04-29 |
CIGB |
|
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 6-10-14 weeks. |
2011-04-27 |
CIGB |
|
Recombinant IFN alpha-2b for relapsing –remitting multiple sclerosis. |
2009-02-11 |
CIGB |
|
Recombinant interferon alpha-2b in paranoid schizophrenia. |
2009-02-11 |
CIGB |
|
Results of an antimicrobial stewardship program |
30/05/2018 |
CenQfal |
|
Retrospective observational study of the administration of Jusvinza, for the management of COVID-19 at the Hospital “Dr. Luis Diaz Soto”. |
29/10/2021 |
CIGB |
|
Safety and immunogenicity of commercial Hepatitis B vaccines. |
2009-02-27 |
CIGB |
|
Safety and Pharmacology of CIGB-300 in cervical cancer (CERVIFARM-300 Study) |
2013-01-18 |
CIGB |
|
Safety assessment of Granulocyte Colony Stimulating Factor:ior LeukoCIM in oncohematologic patients.Phase IV study. |
2009-07-24 |
CIMAB |
|
Seawater-Rhinitis-Children-Phase III |
25/09/2015 |
UDEA |
|
Second Line-Acute Asthma |
09/07/2020 |
SAHUAPA |
|
Sinopharm-SOBERANA COVID-Cienfuegos |
30/08/2022 |
FINLAY |
|
SOBERANA 01A |
17/10/2020 |
FINLAY |
|
SOBERANA 01B |
05/01/2021 |
FINLAY |
|
SOBERANA 02 |
27/10/2020 |
FINLAY |
|
SOBERANA 02-FaseIII |
03/03/2021 |
FINLAY |
|
SOBERANA 02A |
17/12/2020 |
FINLAY |
|
SOBERANA PEDIATRIA |
10/06/2021 |
FINLAY |
|
SOBERANA PLUS |
09/04/2021 |
FINLAY |
